SFSylvie Forlani

Sylvie Forlani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sylvie Forlani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-read sequencing unravels the complexity of structural variants in PRKN in two individuals with early-onset Parkinson’s disease

    by Guillaume Cogan, Kensuke Daida, Kimberley J. Billingsley, Christelle Tesson, Sylvie Forlani, Ludmila Jornea, Lionel Arnaud, Laurene Tissier, Eric LeGuern, Andrew B. Singleton, et al.

    Background: PRKN biallelic pathogenic variants are the most common cause of autosomal recessive early-onset Parkinson’s disease (PD). However, the variants responsible for suspected PRKN- PD individuals are not always identified with standard genetic testing. Objectives: Identify the genetic cause in two siblings with a PRKN -PD phenotype using long-read sequencing (LRS). Methods: The genetic investigation involved standard testing using successively multiple ligation probe amplification (MLPA), Sanger sequencing, targeted sequencing, whole-exome sequencing and LRS. Results: MLPA and targeted sequencing identified one copy of exon four in PRKN but no other variants were identified. Subsequently, LRS unveiled a large deletion encompassing exon 3 to 4 on one allele and a duplication of exon 3 on the second allele; explaining the siblings’ phenotype. MLPA could not identify the balanced rearrangement of exon 3. Conclusions: This study highlights the potential utility of long-read sequencing in the context of unsolved typical PRKN- PD individuals.


  • Gene Activity in the Preimplantation Mouse Embryo

    by Sylvie Forlani, Jean-François Nicolas

    In this review, we describe the functioning of the nuclear material in the mouse from the stage of oocyte maturation to the 2-cell stage. During the past few years, it has been possible to define, using transgenes as a tool, modifications of gene activity in relation to other biochemical events. The part due to cytoplasmic events and the part due to nuclear events have been partially defined. It turns out that the transmission to the zygotic nuclei of information of maternal origin stored in the oocyte and activated after fertilization is crucial at these early stages while nuclear activity is stopped. However, numerous aspects of this period of transition from maternal to embryonic control remain to be described and understood. For instance, the time when the information of maternal origin is relayed to the zygotic nuclei remains to be determined as does the basis of the major change in the pattern of protein synthesis observed in the 2-cell embryo. Future studies based on a more intensive use of transgenes should allow a more comprehensive description of the dynamics of gene activity on which the transition from a gametic to an embryonic state is dependent.

  • A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP

    by Christel Depienne, Estelle Fedirko, Jean-Marc Faucheux, Sylvie Forlani, Bernard Bricka, Cyril Goizet, Sylvie Lesourd, Giovanni Stevanin, Merle Ruberg, Alexandra Durr, et al.

    SPG4/SPAST, the gene-encoding spastin, is responsible for the most frequent form of autosomal dominant hereditary spastic paraplegia (HSP). SPG4-HSP is a heterogeneous disorder characterized by both interfamilial and intrafamilial variation, especially regarding the severity and the age at onset. In this study, we investigated the origin of the mutation and the factors involved in intra-familial heterogeneity in a family with a SPG4 mutation. We demonstrated that the mutation occurred de novo and show evidence of somatic mosaicism in the grandfather, who was the only affected member of six siblings. His disease began at age 55, much later than in his daughter, who had onset at age 18, and his grandson, in whom onset was at age 5. These observations indicate that de novo mutations can occur in SPG4, and that somatic mosaicism might account for intra-familial variation in SPG4-linked HSP.